# Capital Community Angel Investors

> Capital Community Angel Investors is a VC fund backing Medical and Marketing. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: East Lansing, United States
- Total investments: 17
- Last investment: Mar 2023
- Lead investor: 0%
- Last updated: Aug 2026
- X (Twitter): https://twitter.com/CCangelinvestor
- Website: http://ccangels.org
- Facebook: https://www.facebook.com/capitalcommunityangels/

Capital Community Angel Investors (CCAI) is a nonprofit organization that seeks to introduce qualified entrepreneurs to its member investors. The group looks for Michigan-based “disruptive” early stage investments that offer sustainable competitive advantage. We do not consider investments in companies located primarily outside of Michigan, orcompanies in service industries such as real estate, retail businesses, restaurants, or other “lifestyle” enterprises.The members of CCAI are individual investors seeking to fund innovative early stage ventures and startups. Potential members should either have prior early stage investment experience or have a strong desire and capability to learn about and engage in such investments. Our members share the responsibilities associated with evaluating the merits of potential investments, but each member individually decides whether to participate in each investment opportunity. Given the obvious risk of early stage ventures and startups, members must qualify as an accredited investor, as defined under Rule 501 of SEC Regulation D.

## Contacts

5 contacts available for Capital Community Angel Investors. Shizune tracks 1 team members at Capital Community Angel Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/capital-community-angels-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 12% |
| Marketing | 2 | 12% |
| Health Care | 2 | 12% |
| Biotechnology | 2 | 12% |
| Manufacturing | 2 | 12% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Funding Round | 4 | 24% |
| Convertible Note | 3 | 18% |
| Series B | 2 | 12% |
| Series C | 2 | 12% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Travis stoliker | Angel Investor | 0 | https://shizune.co/investors/profile/travis-stoliker |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M | Series C | Mar 08, 2023 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $46.9M | Series B | Dec 22, 2020 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $3M | Convertible Note | Aug 22, 2019 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $4.3M | Series A | May 17, 2017 |  |
| VNN | VNN is the largest and fastest growing high school sports marketing platform in America. As the exclusive web/mobile platform for over 7million passionate fans across 40+ states (adding 8,000 fans daily), VNN is rapidly aggregating the fragmented, multi-billion dollar high school sports market onto an intelligent platform that transforms theconsumer experience of high school sports. | $3.7M |  | Sep 03, 2015 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $3.5M | Debt Financing | Sep 03, 2015 |  |
| Avegant | Avegant is a technology company developing next-generation display technology to enable previously impossible augmented reality experiences. The company uses its deep scientific understanding of human sight and head-mounted display ergonomics together with its consumer electronics manufacturing experience to develop displays that enable realisticAR experiences for consumers.Avegant was founded in 2012 and headquartered in Belmont, California. | $9.4M | Series A | Nov 04, 2014 |  |
| Vestaron | Vestaron produces insecticides for agriculture, animal health, non-crop, and commercial pest control applications. Vestaron Corporation develops and produces insecticides by employing peptides sourced from spiders in the United States. Its products are used in agriculture, animal health, and specialty non-crop applications, as well as in-householdinsects and commercial pest control applications. Vestaron Corporation was formerly known as Venomix, Inc. and changed its name to Vestaron Corporation in August 2009. The company was founded in 2005 and is headquartered in Kalamazoo, Michigan. |  | Series C | Aug 21, 2014 |  |
| ONL Therapeutics | ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $501.8K | Seed | Jul 02, 2014 |  |
| VNN | VNN is the largest and fastest growing high school sports marketing platform in America. As the exclusive web/mobile platform for over 7million passionate fans across 40+ states (adding 8,000 fans daily), VNN is rapidly aggregating the fragmented, multi-billion dollar high school sports market onto an intelligent platform that transforms theconsumer experience of high school sports. | $3M | Series A | Feb 17, 2014 |  |

10 of 17 investments shown.

## Co-investors
- [Michigan Angel Fund](https://shizune.co/investors/profile/michigan-angel-fund) — VC Fund, 4 deals together
- [Biosciences Research and Commercialization Center (BRCC)](https://shizune.co/investors/profile/biosciences-research-and-commercialization-center-brcc) — VC Fund, 3 deals together
- [ExSight Ventures](https://shizune.co/investors/profile/exsight-ventures) — VC Fund, 3 deals together
- [MINTS](https://shizune.co/investors/profile/mints) — VC Fund, 3 deals together
- [Arsenal Growth Equity](https://shizune.co/investors/profile/arsenal-venture-partners) — VC Fund, 2 deals together
- [Bios Partners](https://shizune.co/investors/profile/bios-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Capital Community Angel Investors invest in?

Capital Community Angel Investors invests primarily in Medical, Marketing and Health Care startups, most often at Series A and Funding Round stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Capital Community Angel Investors?

Public channels for Capital Community Angel Investors include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Capital Community Angel Investors?

The team at Capital Community Angel Investors includes Travis stoliker (Angel Investor). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co